Abuse-Deterrent Formulation of OxyContin Linked to Surge in Hepatitis C Infection

The remanufacturing of OxyContin into an "abuse-deterrent formulation" has been identified as a key contributing factor in opioid abusers switching to heroin injections and the corresponding surge in hepatitis C virus (HCV) infections, in a new Rand Corporation study.

Although injection drug use has previously been identified as a predominant risk factor for HCV infection and the opioid epidemic has been suggested as a driver of the recent rise in infections, David Powell, PhD, Senior Economist at the Rand Corporation, Arlington Virginia, and colleagues noted that increased HCV infections appeared to coincide with the reformulation of OxyContin.

"While opioid overdoses and addiction increased steadily in the 2000's—primarily driven by the misuse of opioid analgesics (that is, their use for non-medical reasons)—rates of hepatitis C infections were stagnant or in decline before 2010," Powell and colleagues observed. "It was not until 2010 when OxyContin—one of the most commonly misused opioid analgesics—became reformulated, that the infections began to surge."

To test for a causal relation, the investigators analyzed differences in infection rates between states with different rates of OxyContin misuse prior to reformulation. They assumed that if the reformulation was a principle factor in the increased rate of infection, they would find a higher impact in the states with higher levels of OxyContin misuse prior to reformulation.

The investigators obtained the rate of new acute HCV infections in each state from the National Notifiable Diseases Surveillance System administered by the Centers for Disease Control and Prevention (CDC). Their measure of non-medical use of OxyContin and other analgesics was drawn from self-reported data of the public-use National Survey on Drug Use and Health.

Several measures were taken to validate the comparative analysis, including testing whether the nonmedical use of other analgesics such as hydrocodone, tramadol, and morphine predicted HCV infections following the OxyContin reformulation. In addition, their analysis controlled for contemporary changes in opioid use policies and enforcement practices, such as prescription drug monitoring programs, pain clinic regulations, and disruption of major "pill-mill" operations.

Powell and colleagues found that incidents of OxyContin misuse fell by more than 40% after reformulation, in data collected between 2010 and 2015, and that this coincided with sharp increases in both heroin-related mortality and HCV infections. In the comparison between states, the investigators found that those with above-median OxyContin misuse before the reformulation experienced a 222% increase in HCV infections in the post-reformulation period. In contrast, the states with below-median misuse experienced a 75% increase. That difference did not coincide with other pain reliever misuse and remained when several other potential confounders were accounted for.

"These results show that efforts to deter misuse of opioids can have unintended, long-term public health consequences," Powell said in a statement. "As we continue to develop policies to combat the opioid epidemic, we need to be careful that new approaches do not make another public health problem worse."

Rosalie Pacula, PhD, Senior Economist at the Rand Corporation, Santa Monica, California and a co-author of the study, elaborated on the need to go beyond deterrent measures and abuse deterrent formulations.

"It is important that strategies that limit the supply of abusable prescription opioids are paired with polices to ease the harms associated with switching to illicit drugs, such as improved access to drug treatment and increased efforts to identify and treat diseases associated with injection drug use," Pacula said.

The study, “A Transitioning Epidemic: How the Opioid Crisis is Driving the Rise in Hepatitis C,” was published in Health Affairs.
 

This article was originally published by MD Magazine.




Stay up to date on the latest news in specialty pharmacy by getting Specialty Pharmacy Times in your mailbox or inbox for free!

Click here to sign up for free for the bi-monthly Specialty Pharmacy Times print journal delivered to your address.

Click here to sign up for our email newsletters delivered every Monday, Wednesday, and Friday, in addition to breaking news alerts.

Click here to follow us on Facebook. 

Click here to follow us on Twitter. 

Click here to join our LinkedIn group. 


Most Popular

Related Articles

A novel method of inactivating hepatitis C virus in donor lungs could increase transplantations for patients with end stage lung disease.
Sofosbuvir-based regimens for the treatment of hepatitis C were well tolerated in Asian American communities, according to a new study.
Those with hepatitis B virus have a significantly elevated risk for developing any type of age-related macular degeneration, according to a new report
Company Profile >
Industry Guide >
Market News >
Peer Exchange >
Conferences >
Subscribe >
Specialty Times Resources
About Us
Advertise
Careers
Contact Us
Terms & Conditions
Privacy
MJH Associates >
Pharmacy Times
OTCGuide
American Journal of Managed Care
Cure
MD Magazine
ONCLive
Targeted Oncology
Physicians' Education Resource
Pharmacy & Healthcare Communications, LLC
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 609-716-7777
F: 609-716-4747

Copyright Specialty Pharmacy Times 2006-2018
Pharmacy & Healthcare Communications, LLC. All Rights Reserved.
 

$vacMongoViewPlus$